Tegoprubart Shows Superior Kidney Function Preservation Over Tacrolimus in First Transplant Trial
Source Summary
The phase 2 BESTOW trial found that tegoprubart, a novel anti-CD40L antibody therapy, preserved kidney function better than tacrolimus in adults receiving their first kidney transplant. Kidney graft function remained statistically significantly higher in tegoprubart-treated patients at 18 months, and tegoprubart also produced greater improvements in patient-reported health-related quality of life. Results will be presented at ASN Kidney Week 2026 in October.
Why it matters
Tegoprubart's superior preservation of kidney graft function and improved quality of life could offer a more effective immunosuppressive option for first-time kidney transplant recipients, potentially extending graft survival and patient outcomes.
